Showing 2901-2910 of 5805 results for "".
- Cipher Launches Bionect Foamhttps://practicaldermatology.com/news/cipher-launches-bionect-foam/2458678/Cipher Pharmaceuticals’ prescription topical Bionect® is now available in the US in a lightweight foam preparation that holds its shape until application. The company says the for
- FDA Approves Allergan's Aczone Gel, 7.5% for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-allergans-aczone-gel-75-for-acne-vulgaris/2458681/The FDA approved Allergn’s Aczone (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older. Aczone Gel, 7.5% delivers proven efficacy to treat both inflammatory and non-inflammatory acne, with a new concentration of dapsone in just once-a-day
- Neutrogena® Launches First-Ever Global Beauty Campaignhttps://practicaldermatology.com/news/neutrogena-launches-first-ever-global-beauty-campaign/2458684/Neutrogena® is set to debut their first-ever global campaign: “Neutrogena. See What’s Possible.™” A commercial voiced by Brand Ambassador and creative consultant Kerry Washington will fe
- NOVAN: First Patient Dosed in Phase 3 Program for SB204https://practicaldermatology.com/news/novan-first-patient-dosed-in-phase-3-program-for-sb204/2458688/The first patient has been dosed in a Phase 3 study of Novan’s investigational topical nitric oxide acne gel, Novan, Inc. reports. Novan is running two identically designed Phase 3 pivotal trials in parallel to evaluate the effic
- Botox Helps Fuel Allergan's “Better-Than-Expected” Q4 Earningshttps://practicaldermatology.com/news/botox-helps-fuel-allergans-better-than-expected-q4-earnings/2458687/Allergan is reporting “better-than-expected” fourth-quarter earnings, largely fueled by Botox. The company saw a 74 percent increase in Q4 net revenue to $4.2 Billion for Q4 2015, topping the nearly $4.18 billion consensus estimate of S&a
- Sturge-Weber Foundation to Host Dermatology Roundtablehttps://practicaldermatology.com/news/sturge-weber-foundation-to-host-dermatology-roundtable/2458697/The Sturge-Weber Foundation (SWF) is holding a Dermatology Discussion Roundtable meeting on March 5, 2016, at the Marriott Marquis in Washington, DC. Attendees of the American Academy of Dermatology (AAD) conference are invited to attend this breakfast meeting from 7:30 a.m. to 9:30 a.m. in the J
- FDA Accepts Allergan's sNDA for TEFLARO Use in Childrenhttps://practicaldermatology.com/news/fda-accepts-allergans-snda-for-teflaro-use-in-children/2458700/The U.S. Food and Drug Administration (FDA) has accepted Allergan’s supplemental New Drug Application (sNDA) for IV antibacterial TEFLARO® (ceftaroline fosamil). If approved, this filing will expand the label of TEFLARO beyond adults to include children two months of age a
- Novel Jasmonate Compound Takes On Fine Wrinkles, Poreshttps://practicaldermatology.com/news/novel-jasmonate-compound-takes-on-fine-wrinkles-pores/2458704/The active ingredient in Lancome’s Visionnaire family of products safely and effectively helps improve the appearance of fine wrinkles, skin tone and pores
- Biosimilar News: Sandoz Acquires Biosimilar Infliximab In EEA, FDA Panel Urges Approval of Biosimilar Infliximab in UShttps://practicaldermatology.com/news/biosimilar-new-sandoz-acquires-biosimilar-infliximab-in-eea-fda-panel-urges-approval-of-biosimilar-infliximab-in-us/2458705/Two days after a US Food and Drug Administration (FDA) advisory panel voted to recommend approval of the biosimilar form of Remicade (Infliximab), Novartis’ Sandoz unit has acquired rights to develop and commercialize a biosimilar to Remicade® (i
- Traffic-related Air pollution Linked to Facial Lentigeneshttps://practicaldermatology.com/news/traffic-related-air-pollution-linked-to-facial-lentigenes/2458707/High levels of traffic-related air pollution and air pollution-associated gases may increase risk of developing facial lentigenes, new research suggests. "While NO2 exposure is known to be associated with low lung function and lung cancer, the effect o